SCHEMBL6094022

SCHEMBL6094022

Cc1[nH]c2ccccc2c1C1=C(Cl)C(=O)C=C(Cl)C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.51
HKDC1 Q2TB90 1/20 0.51
LMNA P02545 3/20 0.45
IMPDH2 P12268 1/20 0.42
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
AHR P35869 1/20 0.40
HTT P42858 2/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 2/20 0.39
EIF2AK2 P19525 1/20 0.39
PTGS2 P35354 1/20 0.39
GAA P10253 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29690580 1.00 CCR6 (0.51) CCR6HKDC1LMNAIMPDH2ALDH1A1
SCHEMBL29690625 0.89 CCR6 (0.51) CCR6HKDC1LMNAIMPDH2ALDH1A1
SCHEMBL6094704 0.84 LMNA (0.46) LMNAALDH1A1KMT2AMEN1MAPT
SCHEMBL6094738 0.84 MITF (0.40) CCR6HKDC1LMNAMAPTHSD17B10
SCHEMBL6096284 0.84 HSD17B10 (0.42) LMNAALDH1A1KMT2AKDM4EMEN1
SCHEMBL6097108 0.83 PTPRC (0.54) ALDH1A1KDM4EMAPTHPGDHTT
SCHEMBL6097547 0.83 CCR6 (0.39) CCR6HKDC1LMNAALDH1A1KMT2A
SCHEMBL6096055 0.83 PTPRC (0.37) CCR6HKDC1LMNAALDH1A1KMT2A
SCHEMBL28620116 0.82 LMNA (0.49) CCR6HKDC1LMNAIMPDH2ALDH1A1
SCHEMBL6097317 0.81 AHR (0.43) ALDH1A1KMT2AKDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
US-7057052-B2 Heterocyclic quinones as pharmaceutical agents DUKE UNIVERSITY (US) 2006-06-06 US disclosed
WO-2004050014-A2 SETEROCYCLIC QUINONES AS PHARMACEUTICAL AGENTS DUKE UNIVERSITY (US) 2004-06-17 WO disclosed
US-20040063774-A1 Heterocyclic quinones as pharmaceutical agents DUKE UNIVERSITY 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063774-A1 Heterocyclic quinones as pharmaceutical agents NQO1, RECQL, SDHA CCR6 4533/4885HKDC1 2099/4885LMNA 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.